ST Infrastructure: Mecamfenide sodium for injection receives approval number from the US FDA.

ST Renfu Announcement: Renfu Pharmaceutical Co., Ltd., a holding subsidiary of Yichang Renfu Pharmaceutical Co., Ltd., has received approval from the U.S. Food and Drug Administration for the registration number of injection micafungin sodium. The drug has been approved for the treatment of candidemia, acute disseminated candidiasis, candida peritonitis, and abscess in adults and pediatric patients aged 4 months and older. Yichang Renfu submitted a marketing authorization application to the FDA in September 2024, with a total research and development investment of approximately 6.8 million RMB. According to IQVIA data, the annual sales of injection micafungin sodium in the U.S. market in 2024 are estimated to be around 67 million USD.